CombinatoRx Abstract Accepted for Oral Presentation at ACR 2009

October 8, 2009 7:30 AM EDT

-- Synavive(TM) (CRx-102) Phase 2 Extension Clinical Trial 3-12 Month Results to be Presented --

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that its abstract entitled, "CRx-102 (Prednisolone/Dipyridamole Combination) Enhances Glucocorticoid (GC) Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Results", has been accepted for oral presentation at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia on October 20, 2009. The abstract can be accessed online at http://www.rheumatology.org/annual/index.aspwww.eular.org by clicking on "search abstracts" and entering the author name or abstract number.

Oral Presentation:

    --  Abstract #1943: "CRx-102 (Prednisolone/Dipyridamole Combination)
        Enhances Glucocorticoid (GC) Efficacy and Reduces Adverse Effects in OA
        Therapy: 3-12 Month Results," Huttner, et.al, Tuesday, October 20, 2009:
        5:15 PM Room 108 B, Pennsylvania Convention Center.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action, striking at the biological complexities of human disease. The CombinatoRx proprietary drug discovery technology provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx, please visit www.combinatorx.com.

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx and its Synavive product candidate. These forward-looking statements about future expectations, plans and prospects of CombinatoRx, and its Synavive product candidate involve significant risks, uncertainties and assumptions, including risks related to CombinatoRx's ability to further develop and obtain regulatory approval for the sale of Synavive and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. These forward looking statements reflect management's current views and CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(c) 2009 CombinatoRx, Incorporated. All rights reserved.

    Source: CombinatoRx, Incorporated

Related Categories

Press Releases

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?